UK's Cambridge Nutritional Sciences H1 revenue falls 39% on weak China demand
Overview
UK medical diagnostics firm's H1 revenue fell 39% yr/yr amid lower orders in most regions
Adjusted EBITDA swung to a loss from a profit a year ago
Gross margin slipped to 66.4% from 67.7% due to lower sales
Outlook
Company still expects full-year sales to be lower than previous yr due to market headwinds
Policy changes in China expected to disrupt demand for several years
Company expects H2 adjusted EBITDA near breakeven and gross margins to hold
Result Drivers
WEAK DEMAND - Co said global economic pressures reduced consumer willingness to spend on premium tests, leading to lower orders in many markets
REGIONAL WEAKNESS - Lower orders in Asia, especially China, Thailand, Korea and Indonesia, were main contributors to revenue decline
COST CUTTING - Co reduced administration costs by £0.5m yr/yr through restructuring efforts
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
H1 Gross Margin | 66.40% | ||
H1 Revenue | £2.4 mln |
Analyst Coverage
The one available analyst rating on the shares is "strong buy"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."
Wall Street's median 12-month price target for Cambridge Nutritional Sciences PLC is GBp3.00, about 93.5% above its November 9 closing price of GBp1.55
Reuters Recommended Reads
Nov 9 - UK's Mereo BioPharma Q3 revenue beats expectations
Nov 9 - UK's Kainos Group H1 revenue rises 37% on public sector contracts
Nov 9 - German exports rise more than expected in September
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)